Seeing Is Believing
Currently out of the existing stock ratings of Peter Verdult, 11 are a BUY (52.38%), 8 are a HOLD (38.1%), 2 are a SELL (9.52%).
Analyst Peter Verdult, currently employed at CITI, carries an average stock price target met ratio of 20% that have a potential upside of 3.69% achieved within 36 days.
Peter Verdult’s has documented 41 price targets and ratings displayed on 6 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on SNY, Sanofi ADR at 31-Oct-2023.
Analyst best performing recommendations are on NVO (NOVO NORDISK A/S).
The best stock recommendation documented was for NVO (NOVO NORDISK A/S) at 3/2/2022. The price target of $59.68 was fulfilled within 36 days with a profit of $8.62 (16.88%) receiving and performance score of 4.69.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$30
$2.87 (10.58%)
$38
23 days ago
(01-Nov-2024)
11/14 (78.57%)
$3.11 (11.57%)
23
Hold
$38
$10.87 (40.07%)
$38
7 months 2 days ago
(22-Apr-2024)
0/2 (0%)
$8.93 (30.72%)
Sell
$31
$3.87 (14.26%)
$44
7 months 23 days ago
(01-Apr-2024)
6/9 (66.67%)
$-1.48 (-4.56%)
14
Hold
$37
$9.87 (36.38%)
$40
11 months 19 days ago
(05-Dec-2023)
11/13 (84.62%)
$-1.79 (-4.61%)
22
Hold
$44.45
$17.32 (63.84%)
$73.23
1 years 3 months ago
(24-Aug-2023)
0/2 (0%)
$7.09 (18.98%)
What Year was the first public recommendation made by Peter Verdult?